AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

677.090

-12.459-1.81%

Number of Gainers:6

Number of Losers:18

Number of Flat:19

PE:- -

High:696.579

Open:696.519

Low:673.289

Close:689.549

Volume:25.15M

Turnover:50.86M

Market Cap:97.12B

Float Cap:93.96B

Loading ...

Imricor's Stock Weakness Creates 'Great Buying Opportunity'

ASX Growth Companies With High Insider Ownership September 2026

Simply Wall St.

3 Australian Biotech Stocks With Up To 77% Fair Value Upside

Simply Wall St.

Thailand Posts $2.4 Billion Current Account Surplus in August

MT Newswires Live

CSL Still Generates Caution Despite Rerate

Immutep Receives A$ 856,669 Australian R&D Tax Incentive Cash Rebate

Cann Group Files 2026 Corporate Governance Statement With ASX

Mayne Pharma Group Settles Patent Litigation With Sun Pharmaceutical Industries

MT Newswires Live

Paradigm Biopharmaceuticals Says Board Initiates Voluntary Administration

Mayne Pharma Group - Settlement Does not Include Financial Payment or Upfront Monetary Consideration

THOMSON REUTERS

Mayne Pharma Group - Generic Imvexxy Agreed Market Entry Date Set for 21 October 2032

THOMSON REUTERS

Paradigm Biopharmaceuticals Ltd-Board Initiates Voluntary Administration

THOMSON REUTERS

Paradigm Biopharmaceuticals - Board Intends to Develop Proposal for Deed of Company Arrangement

THOMSON REUTERS

Paradigm Biopharmaceuticals - Clinical Review and Restructuring Process Expected to Take at Least Eight Weeks

THOMSON REUTERS

Paradigm Biopharmaceuticals - Securities Remain Suspended from Trading on ASX During Administration

THOMSON REUTERS

4DMedical And 2 Other Australian Growth Stocks To Own

Simply Wall St.

CSL Seqirus Expands U.S. Availability of Influenza Vaccine Following Successful Completion of the 2026/27 Manufacturing Campaign

THOMSON REUTERS

CSL Partners With Amazon Web Services

MT Newswires Live

CSL Ltd and AWS Collaborate to Advance Biopharmaceutical Research and Development

Neuren Says US Patent Allowance Could Extend Trofinetide Protection to 2041

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":677.0902,"timestamp":1790818122513,"preClose":689.5493,"halted":0,"volume":25151273,"delay":0,"changeRate":-0.018068,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-12.459106,"latestTime":"10-01 11:28:43 AEST","open":696.5189,"high":696.5787,"low":673.28906,"amount":50855024,"amplitude":0.033775,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790834400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1790812800000,1790834400000]],"turnoverRate":0.001,"increases":7,"decrements":18,"flats":17,"marketCap":97116470526,"floatMarketCap":93962623987.6875},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":696.5787,"amplitude":0.033775,"preClose":689.5493,"low":673.28906,"latestPrice":677.0902,"volume":25151273,"delay":0,"open":696.5189,"prevYearClose":644.3692,"prevWeekClose":662.842,"prevMonthClose":689.549,"prevQuarterClose":689.549,"fiveDayClose":672.425,"twentyDayClose":670.585,"sixtyDayClose":506.934,"secType":"PLATE","market":"AU","turnoverRate":0.001,"marketCap":97116470526,"floatMarketCap":93962623987.6875,"timestamp":1790818122513,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":6,"down":18,"flat":19},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672710738","title":"Imricor's Stock Weakness Creates 'Great Buying Opportunity'","url":"https://stock-news.laohu8.com/highlight/detail?id=2672710738","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672710738?lang=en_us&edition=fundamental","pubTime":"2026-10-01 07:18","pubTimestamp":1790810280,"startTime":"0","endTime":"0","summary":"2318 GMT - A more than 20% fall in the share price of Imricor Medical Systems since it entered the ASX 300 index in early September creates a great buying opportunity for investors, according to its bull at Morgans. Imricor ended Wednesday at A$1.585, having traded as high as A$2.07 in August. Morgans suggests seasonal weakness and rising interest rates may have contributed to the share-price fall. Recent news flow has been positive. \"As we move into a seasonally stronger part of the year, together with our view that material news flow  is expected, we believe the share price should move back over A$2.00,\" Morgans' analyst Scott Power says. Morgans has a speculative buy call on Imricor.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","BK7503","IMR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672411738","title":"ASX Growth Companies With High Insider Ownership September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2672411738","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672411738?lang=en_us&edition=fundamental","pubTime":"2026-10-01 03:08","pubTimestamp":1790795293,"startTime":"0","endTime":"0","summary":"In the wake of the recent RBA rate increase, the Australian market is experiencing a period of volatility, with mixed signals from global markets and fluctuating commodity prices adding to investor uncertainty. Amidst these conditions, growth companies with high insider ownership can offer unique insights into potential resilience and alignment between management and shareholder interests, making them noteworthy in today's economic climate.","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/asx-growth-companies-with-high-insider-ownership-september-2-5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/asx-growth-companies-with-high-insider-ownership-september-2-5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ELS.AU","GYG.AU","IQ","GEAR.AU","STW.AU","OZR.AU","OZF.AU","XKO.AU","IIGF.AU","XAO.AU","BK4531","BK4526","BK7023","BEAR.AU","EIGA.AU","BK7508","EMR.AU","BK4108","SPL.AU","BK7084","EIQ.AU","VAS.AU","FRS.AU","AR1.AU","IISV.AU","AV1.AU","IMLC.AU","BK7104","BK7093","SKS.AU","BK4552","BK7501","XJO.AU","PDI.AU","BK7095","BK7017","MSB.AU","VAP.AU","BK7137","IOZ.AU","SLF.AU","WZR.AU","DACE.AU","AEM.AU","QRE.AU","ZYAU.AU","BBOZ.AU","GIVE.AU","E200.AU","QFN.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672738443","title":"3 Australian Biotech Stocks With Up To 77% Fair Value Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2672738443","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672738443?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:20","pubTimestamp":1790763656,"startTime":"0","endTime":"0","summary":"Australia’s inflation rate sitting at 4% and interest rates at a 15 year high of 4.6% are squeezing many growth stories. Yet that pressure also pushes investors toward companies with solid balance sheets and clear funding runways. That matters for Australian biotechnology stocks, where capital access can make or break a breakthrough. This article highlights three listed biotech opportunities screened for financial resilience and reasonable value.\nThe three biotech stocks covered below are a...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-up-to-77-fair-value-upside","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-up-to-77-fair-value-upside","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["OZF.AU","ZYAU.AU","IMLC.AU","BK7096","GIVE.AU","BK4588","XKO.AU","VLS.AU","BBOZ.AU","MYX.AU","DACE.AU","VAP.AU","CUV.AU","E200.AU","BK4581","NVIB","XAO.AU","VAS.AU","IISV.AU","BK7508","BEAR.AU","GEAR.AU","BK7067","XJO.AU","EIGA.AU","QFN.AU","QRE.AU","IOZ.AU","XBI","IIGF.AU","BK4585","XBIX","SLF.AU","OZR.AU","STW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671827184","title":"Thailand Posts $2.4 Billion Current Account Surplus in August","url":"https://stock-news.laohu8.com/highlight/detail?id=2671827184","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671827184?lang=en_us&edition=fundamental","pubTime":"2026-09-30 15:55","pubTimestamp":1790754907,"startTime":"0","endTime":"0","summary":"Thailand's current account position recorded a surplus of $2.4 billion in August, according to data from the Bank of Thailand (BOT) released on Wednesday.The reading compared with a $1.6 billion deficit recorded in the previous month.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BOT","BK7502","BK7508","BK7096","BOT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671227775","title":"CSL Still Generates Caution Despite Rerate","url":"https://stock-news.laohu8.com/highlight/detail?id=2671227775","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671227775?lang=en_us&edition=fundamental","pubTime":"2026-09-30 12:52","pubTimestamp":1790743920,"startTime":"0","endTime":"0","summary":"0452 GMT - CSL still generates caution at Macquarie despite the stock's recent rerate. Analysts at the investment bank keep a neutral rating on the Australia-based pharmaceutical company, observing that a 58% share-price rise over three months came despite earnings downgrades. They think that near-term catalysts will probably support the current rerating, but tell clients in a note that they are cautious on the medium-term outlook due to uncertainty over the impact on demand of complement-inhibitor therapies, albumin collections, and the process to appoint a new permanent CEO. Macquarie raises its target price on the stock 31% to 174.00 Australian dollars. Shares are up 1.4% at A$184.25.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","CSL.AU","BK7067","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671226246","title":"Immutep Receives A$ 856,669 Australian R&D Tax Incentive Cash Rebate","url":"https://stock-news.laohu8.com/highlight/detail?id=2671226246","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671226246?lang=en_us&edition=fundamental","pubTime":"2026-09-30 09:15","pubTimestamp":1790730903,"startTime":"0","endTime":"0","summary":"Immutep receives A$ 856,669 Australian R&D tax incentive cash rebateImmutep received an A$ 856,669 cash rebate under Australia’s R&D tax incentive program for eligible 2025 fiscal-year spending.AusInd","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL3wCmPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671299242","title":"Cann Group Files 2026 Corporate Governance Statement With ASX","url":"https://stock-news.laohu8.com/highlight/detail?id=2671299242","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671299242?lang=en_us&edition=fundamental","pubTime":"2026-09-30 09:07","pubTimestamp":1790730434,"startTime":"0","endTime":"0","summary":"Cann Group ( ($AU:CAN) ) has provided an update. Cann Group Limited has lodged its corporate governance statement for the year ended 30 June 2026, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cann-group-files-2026-corporate-governance-statement-with-asx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cann-group-files-2026-corporate-governance-statement-with-asx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK7096","BK7502","BK7508","CAN.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671226535","title":"Mayne Pharma Group Settles Patent Litigation With Sun Pharmaceutical Industries","url":"https://stock-news.laohu8.com/highlight/detail?id=2671226535","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671226535?lang=en_us&edition=fundamental","pubTime":"2026-09-30 08:55","pubTimestamp":1790729716,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  settled Paragraph IV patent litigation with Sun Pharmaceutical Industries concerning Imvexxy, an estradiol vaginal insert used to treat moderate to severe menopause-related dyspareunia, including disputes over patents listed for the drug in the US Food and Drug Administration's Orange Book, according to a Wednesday Australian bourse filing.Sun Pharma's generic version of the treatment may enter the US market on Oct. 21, 2032, or earlier under certain circumstances, subject to court approval, with no financial payment or upfront consideration between the parties, the filing said.The company said the settlement reinforces the validity and enforceability of its patent portfolio covering the product, with the final patent set to expire in February 2034, the filing added.The specialty pharmaceutical company's shares gained about 1% in recent Wednesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7096","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671223116","title":"Paradigm Biopharmaceuticals Says Board Initiates Voluntary Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2671223116","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671223116?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:52","pubTimestamp":1790725977,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Says Board Initiates Voluntary AdministrationSept 30 (Reuters)-Paradigm Biopharmaceuticals LtdPAR.AX:INITIATES VOLUNTARY ADMINISTRATION PROCESSBOARD INTENDS TO DEVELO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUE6WRYYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Paradigm Biopharmaceuticals Says Board Initiates Voluntary Administration","news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","PAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671522319","title":"Mayne Pharma Group - Settlement Does not Include Financial Payment or Upfront Monetary Consideration","url":"https://stock-news.laohu8.com/highlight/detail?id=2671522319","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671522319?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:49","pubTimestamp":1790725788,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45L1TF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671223194","title":"Mayne Pharma Group - Generic Imvexxy Agreed Market Entry Date Set for 21 October 2032","url":"https://stock-news.laohu8.com/highlight/detail?id=2671223194","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671223194?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:49","pubTimestamp":1790725788,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45L1TF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671997223","title":"Paradigm Biopharmaceuticals Ltd-Board Initiates Voluntary Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2671997223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671997223?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:47","pubTimestamp":1790725675,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUE6WRYYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","PAR.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671722391","title":"Paradigm Biopharmaceuticals - Board Intends to Develop Proposal for Deed of Company Arrangement","url":"https://stock-news.laohu8.com/highlight/detail?id=2671722391","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671722391?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:47","pubTimestamp":1790725675,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUE6WRYYG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAR.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671322394","title":"Paradigm Biopharmaceuticals - Clinical Review and Restructuring Process Expected to Take at Least Eight Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2671322394","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671322394?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:47","pubTimestamp":1790725675,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUE6WRYYG:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671223910","title":"Paradigm Biopharmaceuticals - Securities Remain Suspended from Trading on ASX During Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2671223910","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671223910?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:47","pubTimestamp":1790725675,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUE6WRYYG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","PAR.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671277550","title":"4DMedical And 2 Other Australian Growth Stocks To Own","url":"https://stock-news.laohu8.com/highlight/detail?id=2671277550","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671277550?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:21","pubTimestamp":1790724093,"startTime":"0","endTime":"0","summary":"Australia’s interest rate now sits at a 15 year high of 4.6%, which makes dependable earnings growth harder to find and more valuable when you do. Higher borrowing costs punish weak balance sheets, yet stronger businesses with solid finances and clear profit expansion stories can still build wealth. This article highlights three Australian high growth potential stocks from our healthy growth screen that fit that profile.\nThe three stocks covered below are a small sample, with the full healthy...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551730-choice1-card/1788960340613","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551730-choice1-card/1788960340613"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/4dmedical-and-2-other-australian-growth-stocks-to-own","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/4dmedical-and-2-other-australian-growth-stocks-to-own","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7503","DECU","SLF.AU","PMDE","VAP.AU","VAS.AU","IISV.AU","BK7508","GIVE.AU","BK7096","IOZ.AU","VOTE","XAO.AU","BK7094","FEBU","E200.AU","BK7043","VGFPF","ZYAU.AU","STW.AU","4DX.AU","OZF.AU","IMLC.AU","DACE.AU","NEU.AU","XKO.AU","GXDW","IIGF.AU","GEAR.AU","JOYT","RGLO","BEAR.AU","BBOZ.AU","QRE.AU","XJO.AU","QFN.AU","OZR.AU","MP1.AU","EIGA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671179142","title":"CSL Seqirus Expands U.S. Availability of Influenza Vaccine Following Successful Completion of the 2026/27 Manufacturing Campaign","url":"https://stock-news.laohu8.com/highlight/detail?id=2671179142","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671179142?lang=en_us&edition=fundamental","pubTime":"2026-09-29 21:30","pubTimestamp":1790688611,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45L0VW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","CSL.AU","BK7511","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671126476","title":"CSL Partners With Amazon Web Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2671126476","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671126476?lang=en_us&edition=fundamental","pubTime":"2026-09-29 10:15","pubTimestamp":1790648142,"startTime":"0","endTime":"0","summary":"CSL  partnered with Amazon Web Services to apply artificial intelligence and cloud technologies in advancing its biopharmaceutical research and clinical development, the biotechnology company said in a statement on Tuesday.The collaboration will enable scientists to connect and analyze data, identify targets sooner, accelerate timelines, and assess external opportunities efficiently, while fostering closer links between laboratory and computational work, the statement said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2023250843.SGD","LU1633808545.USD","IE00BQXX3D17.EUR","IE00B7KXQ091.USD","IE00BMPRXQ63.HKD","LU0708994859.HKD","LU2461242641.AUD","LU1244550221.USD","LU0198837287.USD","LU0079474960.USD","LU0672654240.SGD","LU2237957811.SGD","LU2213496289.HKD","IE000WAW04H5.SGD","HK0000304805.HKD","LU1084165304.USD","AMZU","IE00B19Z3581.USD","LU2430703095.HKD","LU0251142724.SGD","LU0256863902.USD","LU1127390331.HKD","LU2023251221.USD","BK4535","LU1720051017.SGD","BK4122","LU0787776722.HKD","LU0648000940.SGD","LU1066051498.USD","WANT","LU2106854487.HKD","LU1868836914.USD","LU1116320901.HKD","LU0310799852.SGD","LU1823568750.SGD","AZYY","LU0158827948.USD","LU2552382132.HKD","LU2168564495.EUR","LU2462591350.SGD","AMZN","IE00B1XK9C88.USD","LU0345774631.USD","IE000M9KFDE8.USD","LU0965509010.AUD","LU1935043452.HKD","LU0265550946.USD","LU0965509101.SGD","LU1261432733.SGD","LU2420271590.USD","LU0029864427.USD","IE000KEQY171.SGD","SG9999015986.USD","BK7501","IE00BQXX3C00.GBP","BK4581","LU2505996681.GBP","LU1244550494.USD","BK4527","LU0289941410.SGD","LU0157215616.USD","IE00B19Z3B42.SGD","LU2317271919.USD","BK7067","LU2360106780.USD","LU0784384876.USD","LU0345768153.USD","LU2111349929.HKD","HK0000914660.USD","BK4524","LU0061475181.USD","LU1037948897.HKD","LU0238689110.USD","LU1883839398.USD","LU2954938101.SGD","LU2746668461.USD","LU0965508806.USD","LU0097036916.USD","LU1280957306.USD","LU1674673428.USD","LU1861558580.USD","LU1066053197.SGD","IE000ITXATA3.USD","LU0080751232.USD","LU0154236417.USD","LU2592432038.USD","LU0072462426.USD","LU0980610538.SGD","IE000W1ABFV2.USD","SG9999015978.USD","AMZZ","LU0889565833.HKD","LU0353189680.USD","LU0724617625.USD","LU0234570918.USD","LU1935043536.SGD","LU2211815571.USD","LU2028103732.USD","IE00BN29S564.USD","BK4561","LU1201861249.SGD","LU1629891620.HKD","IE00B4YYXB79.USD","BK4585","LU2860962120.EUR","LU0211328371.USD","IE0004086264.USD","LU1852331112.SGD","LU1880398471.USD","BK4533","LU0082616367.USD","LU2250418816.HKD","LU2275660780.HKD","LU2417539215.USD","LU0070302665.USD","IE00BKDWB100.SGD","LU1496350171.SGD","LU2362541513.USD","LU2092937148.SGD","IE00B19Z8W00.USD","LU1914381329.SGD","LU0158827781.USD","LU1934455277.USD","LU0345769128.USD","LU0949170426.SGD","LU2125154778.USD","BK4534","LU0742534661.SGD","SG9999000418.SGD","LU1839511570.USD","LU0072461881.USD","IE0004445015.USD","LU2237438978.USD","LU2264538146.SGD","LU0314104364.USD","LU1988902786.USD","BK7508","AMZG","LU0784383803.USD","LU0640476718.USD","LU0234572021.USD","LU2637965513.SGD","LU0096364046.USD","LU0162691827.USD","LU1935043023.USD","IE00BQXX3F31.USD","LU1720051108.HKD","IE00B3SWFQ91.USD","SG9999004303.SGD","BK4220","LU1046421795.USD","LU0985320562.USD","LU1366333091.USD","LU0345770993.USD","LU1267930730.SGD","BK4598","LU1037948541.HKD","IE0001KFT4U8.USD","LU1232071149.USD","LU0642271901.SGD","LU0871640123.AUD","IE00BFSS7M15.SGD","LU1941712348.USD","LU2236285917.USD","AMZO","LU0077335932.USD","LU0823421416.USD","LU0861579265.USD","LU0174119429.USD","LU0267386448.USD","LU0289960550.SGD","LU0308772762.SGD","BK4551","LU2092627202.USD","LU1804176565.USD","IE000MB6IJN5.SGD","LU2168564222.USD","LU2247934214.USD","HK0000914686.HKD","IE00BJTD4N35.SGD","LU2471134952.CNY","LU1267930573.SGD","IE000F7OJYX1.SGD","LU2602419157.SGD","IE00BKPKM429.USD","LU0203201768.USD","BK4538","LU0456855351.SGD","LU0312595415.SGD","LU2750360641.GBP","LU0784385170.HKD","LU2237957902.USD","SGXZ99366536.SGD","LU0320765059.SGD","IE000SO60NU8.SGD","SG9999001077.SGD","SGXZ80539844.SGD","BK7511","LU0011850046.USD","SG9999018865.SGD","ILDR","LU0211327993.USD","IE000YTNTUN2.SGD","LU0048573561.USD","LU2403377893.USD","ONLN","LU2462157665.USD","IE00BJJMRY28.SGD","SG9999014906.USD","LU0708995401.HKD","BK4507","LU0943347566.SGD","LU1935042991.SGD","LU2456880835.USD","IE00B5949003.HKD","LU1941712264.USD","IE00B4JS1V06.HKD","LU1868837136.USD","LU2089283258.USD","LU0256863811.USD","LU2552382058.USD","LU0061474705.USD","LU2168563687.JPY","LU0175139822.USD","LU0957791311.USD","LU0320765489.SGD","LU2471134796.USD","LU2362540622.SGD","BK4596","LU2362541273.HKD","LU0820561818.USD","LU0070217475.USD","LU1674673691.USD","LU1116320737.USD","LU2471134523.USD","RTH","LU2746668974.SGD","IE00BMPRXR70.SGD","LU1917777945.USD","LU2430703251.USD","LU2756315664.SGD","LU2054465674.USD","LU0251132253.USD","IE0004091025.USD","LU0965509283.SGD","LU2065171311.SGD","IE00BK4W5M84.HKD","LU2089284900.SGD","HK0000304797.USD","LU1548497426.USD","LU0390134368.USD","LU0648001328.SGD","SGXZ44715902.SGD","LU2077746001.SGD","IE00BJLML261.HKD","LU1145028129.USD","LU0265550359.USD","LU1979441026.SGD","LU2720916845.USD","LU2087621335.USD","IE00B775H168.HKD","LU1814569148.SGD","IE00B19Z8X17.USD","AMZW","IE00BWXC8680.SGD","LU2271345857.HKD","LU2543165471.USD","LU0061474960.USD","CSL.AU","IE000BZT7R73.USD","BK4543","AMZP","LU1066051225.USD","LU0342679015.USD","LU1323610961.USD","GB00BDT5M118.USD","CLIX","LU2764262908.HKD","LU2357305700.SGD","LU2242649171.HKD","SGXZ51526630.SGD","LU0149725797.USD","IE00BJJMRX11.SGD","BK4550","LU1069344957.HKD","LU1868837300.USD","SG9999017495.SGD","LU0109392836.USD","IE0002270589.USD","LU1066051811.HKD","LU0345770308.USD","LU0354030438.USD","IE0009356076.USD","LU0345774391.USD","LU2999663052.SGD","LU0823434740.USD","LU1435385759.SGD","LU0316494557.USD","LU0251131958.USD","LU0494093205.USD","LU2023250504.SGD","LU0096362180.USD","LU2125154935.USD","LU2265009873.SGD","LU0208291251.USD","HULL","LU1267930490.SGD","LU2360032135.SGD","USAW.SI","LU2452424414.USD","LU0823421333.USD","LU1935042215.USD","LU1778281490.HKD","IE00BJTD4V19.USD","LU0354030511.USD","LU1301847155.USD","BK4532","LU0210528500.USD","LU0348723411.USD","IE00B19Z9505.USD","OGIG","LU2361045086.USD","LU1868836757.USD","LU2764263203.CNY","LU0127658192.USD","LU2097829019.USD","LU1551013342.USD","LU1989764664.SGD","LU0302445910.USD","LU2430703178.SGD","IE00B775SV38.USD","LU0323591593.USD","LU2552382215.SGD","LU0203202063.USD","LU0133085943.USD","LU0964807845.USD","AMAA","LU1815333072.USD","LU0528227936.USD","LU2326559502.SGD","LU1691799644.USD","LU2065169927.USD","BK4554","LU1429558221.USD","SG9999014880.SGD","BK4559","SG9999015952.SGD","LU1064131342.USD","BK4592","SG9999002224.SGD","LU0719512351.SGD","LU0820562030.AUD","IE00B3S45H60.SGD","LU2083900584.USD","IE00B1BXHZ80.USD","LU1496350502.SGD","LU0788109477.HKD","LU0130103400.USD","LU0215105999.USD","IE0005OL40V9.USD","LU1235294995.USD","SGXZ31699556.SGD","IE00B7SZLL34.SGD","LU1974910355.USD","LU0048584097.USD","LU1119994496.HKD","LU2168564149.EUR","IE0004445239.USD","LU1868836591.USD","LU1153585028.USD","IE00BZ1G4Q59.USD","SG9999014898.SGD","LU2065170008.USD","IE00B5TLWC47.USD","LU2168564065.EUR","SG9999002232.USD","IE00BFXG0V08.USD","LU1861559042.SGD","SAMZNmain","IE00BMPRXN33.USD","LU2764263039.SGD","LU0130102774.USD","LU0310800379.SGD","HK0000532082.HKD","LU1934455194.USD","LU2750360997.AUD","LU0107464264.USD","LU2381873111.SGD","LU0784385840.USD","LU0210533765.USD","LU1244550577.SGD","LU0276348264.USD","LU1989764748.USD","BK4604","LU0056508442.USD","BK4503","LU2063271972.USD","LU0689472784.USD","LU2087625088.SGD","LU1366192091.USD","LU1791710582.SGD","BK4588","LU1718418525.SGD","SG9999018857.SGD","LU2211817866.USD","SG9999014914.USD","BK4566","IE0009G5SDU7.USD","LU1935042488.USD","LU0820561909.HKD","LU1551013425.SGD","LU2361044865.SGD","LU2242650005.HKD","LU0053666078.USD","BK4548","LU1201861165.SGD","LU0170899867.USD","LU1035775433.USD","AMZD","LU2505996509.AUD","LU2462591277.SGD","LU1791710400.SGD","LU0417517546.SGD","LU0882574139.USD","IE0034235303.USD","SGXZ23171101.USD","BK4612","LU0128525929.USD","LU1316542783.SGD","LU1074936037.SGD","LU1861127337.USD","LU0823411888.USD","LU0143551892.USD","LU0683600562.USD","BK4579","LU0786609619.USD","LU0109391861.USD","LU0353189763.USD","LU2487616109.SGD","IE0000B7K699.USD","IE00BYQQ9H92.USD","LU0210536198.USD","LU2463028550.USD","LU0466842654.USD","LU2065171402.SGD","LU0345769631.USD","IE00BFSS8Q28.SGD","LU2023250330.USD","LU0823434583.USD","LU2756315318.SGD","LU1934455863.HKD","IE0003U64NQ7.SGD","LU2896262040.SGD","LU2361044949.HKD","LU2108987350.USD","LU2471134879.HKD","LU1880398554.USD","SGXZ81514606.USD","IE00BKVL7J92.USD","SG9999015945.SGD","LU1803068979.SGD","LU0138981039.USD","LU0345768740.USD","IE00BK4W5L77.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671264546","title":"CSL Ltd and AWS Collaborate to Advance Biopharmaceutical Research and Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2671264546","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671264546?lang=en_us&edition=fundamental","pubTime":"2026-09-29 09:58","pubTimestamp":1790647118,"startTime":"0","endTime":"0","summary":"Sept 29 (Reuters) - CSL Limited::*CSL AND AWS COLLABORATE TO ADVANCE BIOPHARMACEUTICAL RESEARCH AND DEVELOPMENT*COLLABORATION WITH AWS TO APPLY ARTIFICIAL INTELLIGENCE AND CLOUD TECHNOLOGIES TO SUPPOR","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nRSD9wgM5F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CSL.AU","BK7511","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671261940","title":"Neuren Says US Patent Allowance Could Extend Trofinetide Protection to 2041","url":"https://stock-news.laohu8.com/highlight/detail?id=2671261940","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671261940?lang=en_us&edition=fundamental","pubTime":"2026-09-29 09:25","pubTimestamp":1790645148,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said partner Acadia Pharmaceuticals received a notice of allowance from the US Patent and Trademark Office for a new US patent covering weight-banded dosing of trofinetide, according to a Tuesday Australian bourse filing.The patent, once issued and with six months of pediatric exclusivity, is expected to extend US patent protection for trofinetide to March 28, 2041, nearly five years beyond the current protection period, the filing said.Trofinetide is marketed in the US under the brand names Daybue and Daybue Stix for patients aged two years and older with Rett syndrome, the filing added.The company's shares rose 2% in recent Tuesday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","USRD","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":70,"code":"91000000","status":"200"}]}}